{"protocolSection": {"identificationModule": {"nctId": "NCT03342690", "orgStudyIdInfo": {"id": "A6141122"}, "organization": {"fullName": "Pfizer", "class": "INDUSTRY"}, "briefTitle": "Drug Use Investigation of Selara Tablets (an Investigation for Chronic Heart Failure)", "officialTitle": "DRUG USE INVESTIGATION OF SELARA(REGISTERED). TABLETS(AN INVESTIGATION FOR CHRONIC HEART FAILURE)"}, "statusModule": {"statusVerifiedDate": "2023-06", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2017-07-05", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2020-07-15", "type": "ACTUAL"}, "completionDateStruct": {"date": "2020-07-15", "type": "ACTUAL"}, "studyFirstSubmitDate": "2017-10-31", "studyFirstSubmitQcDate": "2017-11-13", "studyFirstPostDateStruct": {"date": "2017-11-17", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2021-06-04", "resultsFirstSubmitQcDate": "2021-06-04", "resultsFirstPostDateStruct": {"date": "2021-06-28", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2023-06-26", "lastUpdatePostDateStruct": {"date": "2023-07-11", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "Secondary Data Collection Study; Safety And Effectiveness Of Selara Under Japanese Medical Practice", "detailedDescription": "This study will be conducted under the central registration system until the number of subjects who meet the conditions for registration reaches the target number of subjects. The patients will be observed up until Week 52."}, "conditionsModule": {"conditions": ["Chronic Heart Failure"], "keywords": ["Selara", "Chronic Heart Failure"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "CASE_ONLY", "timePerspective": "PROSPECTIVE"}, "enrollmentInfo": {"count": 1165, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Eplerenone", "description": "Patients with CHF receiving Selara (eplerenone)", "interventionNames": ["Drug: Eplerenone"]}], "interventions": [{"type": "DRUG", "name": "Eplerenone", "description": "In adults, usually, administer the initial dose of 25 mg once daily according to the patient's serum potassium level and conditions, increase dosage up to 50 mg once daily after 4 week; patients with moderate renal impairment should start with 25 mg every other day and the maximum dosage should be 25 mg once daily.\n\nAlso, dose should be reduced or interrupted according to serum potassium level and patient's conditions.", "armGroupLabels": ["Eplerenone"], "otherNames": ["Selara"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Percentage of Participants With Adverse Drug Reactions in Chronic Heart Failure Participants With Moderate Renal Impairment", "description": "An adverse drug reaction (ADR) was any untoward medical occurrence attributed to Selara in a chronic heart failure participant with moderate renal impairment (\u226530 mL/min and \\<50 mL/min in eCLCr) who received Selara. A serious ADR was an ADR resulting in any of the following outcomes or deemed significant for any other reason: death\u037e life-threatening experience (immediate risk of dying)\u037e initial or prolonged inpatient hospitalization\u037e persistent or significant disability/incapacity\u037e congenital anomaly. Relatedness to Selara was assessed by the physician.", "timeFrame": "52 weeks from the start date"}], "secondaryOutcomes": [{"measure": "Percentage of Participants With Adverse Drug Reactions in Chronic Heart Failure Participants", "description": "An adverse drug reaction (ADR) was any untoward medical occurrence attributed to Selara in a chronic heart failure participant who received Selara. A serious ADR was an ADR resulting in any of the following outcomes or deemed significant for any other reason: death\u037e life-threatening experience (immediate risk of dying)\u037e initial or prolonged inpatient hospitalization\u037e persistent or significant disability/incapacity\u037e congenital anomaly. Relatedness to Selara was assessed by the physician.", "timeFrame": "52 weeks from the start date"}, {"measure": "The Number of Deaths (Overall Deaths)", "description": "Overall deaths were described with the number of deaths from any cause at the time of 52 weeks after the start of administration, regardless of the treatment status (completed or discontinued).", "timeFrame": "52 weeks from the start date"}, {"measure": "The Number of Deaths (Cardiovascular Deaths)", "description": "Cardiovascular deaths were described with the number of deaths defined as any death due to cardiac failure, myocardial infarction, arrhythmia (atrial fibrillation, atrial flutter, arrhythmia supraventricular, or ventricular arrhythmia), stroke or cerebrovascular attack, and other causes related to cardiovascular system at the time of 52 weeks after the start of administration, regardless of the treatment status (completed or discontinued).", "timeFrame": "52 weeks from the start date"}, {"measure": "The Overall Mortality Rate", "description": "The overall mortality rate was calculated by the incidence of all-cause death per observation time based on the person-year method (the number of deaths in 100 person-year).", "timeFrame": "52 weeks from the start date"}, {"measure": "The Cardiovascular-related Mortality Rate", "description": "The cardiovascular-related mortality rate was calculated by the incidence of cardiovascular-related death per observation time based on the person-year method (the number of deaths in 100 person-year).\n\nCardiovascular deaths were defined as any death due to cardiac failure, myocardial infarction, arrhythmia (atrial fibrillation, atrial flutter, arrhythmia supraventricular, or ventricular arrhythmia), stroke or cerebrovascular attack, and other causes related to cardiovascular system at the time of 52 weeks after the start of administration, regardless of the treatment status (completed or discontinued).", "timeFrame": "52 weeks from the start date"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patients in whom treatment with this drug is for CHF. The indications at approval for this drug are as follows. When using this drug, refer to the latest package insert of this drug.\n\nExclusion Criteria:\n\n* Patients who were previously registered for this study. Patients who received eplerenone within the past three months regardless of the reason for use.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "0 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"], "studyPopulation": "The patients who meet the inclusion criteria and who were registered to this study within 14 days including the start date of treatment with this product will be subjects for this study", "samplingMethod": "PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"overallOfficials": [{"name": "Pfizer CT.gov Call Center", "affiliation": "Pfizer", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Pfizer Local Country Office", "city": "Tokyo", "country": "Japan", "geoPoint": {"lat": 35.6895, "lon": 139.69171}}]}, "referencesModule": {"seeAlsoLinks": [{"label": "To obtain contact information for a study center near you, click here.", "url": "https://pmiform.com/clinical-trial-info-request?StudyID=A6141122"}]}, "ipdSharingStatementModule": {"ipdSharing": "NO", "description": "Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests."}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Selara Tablets (Eplerenone)", "description": "Participants who received Selara as indicated in the approved local product document were observed for a period of 52 weeks. The dosage can be adjusted as per physician's discretion."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "1164"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1139"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "25"}]}], "dropWithdraws": [{"type": "Missing Information", "reasons": [{"groupId": "FG000", "numSubjects": "9"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "16"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "A total of 1165 participants were enrolled in this study. Of the 1164 participants who completed the study, 25 participants were excluded from the safety analysis set due to the following reasons: protocol violation (16 participants), and no adverse event information (no visit after first day of treatment or unknown) (9 participants).", "groups": [{"id": "BG000", "title": "Selara Tablets (Eplerenone)", "description": "Participants who received Selara as indicated in the approved local product document were observed for a period of 52 weeks. The dosage can be adjusted as per physician's discretion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "1139"}]}], "measures": [{"title": "Age, Customized", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "<15 years", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "1139"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}]}]}, {"title": "\u226515 and <65 years", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "1139"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "219"}]}]}, {"title": "\u226565 years", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "1139"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "920"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "1139"}]}], "categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "516"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "623"}]}]}]}, {"title": "Race and Ethnicity Not Collected", "populationDescription": "Race and Ethnicity were not collected from any participant.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Estimated creatinine clearance (eCLCr)", "description": "The Cockcroft \\& Gault formula was used to eCLCr.", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "<30 mL/min", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "1139"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "92"}]}]}, {"title": "\u226530 mL/min and <50 mL/min", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "1139"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "316"}]}]}, {"title": "\u226550 mL/min", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "1139"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "524"}]}]}, {"title": "Unknown", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "1139"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "207"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Percentage of Participants With Adverse Drug Reactions in Chronic Heart Failure Participants With Moderate Renal Impairment", "description": "An adverse drug reaction (ADR) was any untoward medical occurrence attributed to Selara in a chronic heart failure participant with moderate renal impairment (\u226530 mL/min and \\<50 mL/min in eCLCr) who received Selara. A serious ADR was an ADR resulting in any of the following outcomes or deemed significant for any other reason: death\u037e life-threatening experience (immediate risk of dying)\u037e initial or prolonged inpatient hospitalization\u037e persistent or significant disability/incapacity\u037e congenital anomaly. Relatedness to Selara was assessed by the physician.", "populationDescription": "The safety analysis set comprised of chronic heart failure participants who satisfied the inclusion criteria and had received Selara at least once. Of the participants included in the safety analysis set (n=1139), 316 participants had moderate renal impairment (\u226530 mL/min and \\<50 mL/min in eCLCr).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Participants", "timeFrame": "52 weeks from the start date", "groups": [{"id": "OG000", "title": "Selara Tablets (Eplerenone)", "description": "Participants who received Selara as indicated in the approved local product document were observed for a period of 52 weeks. The dosage can be adjusted as per physician's discretion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "316"}]}], "classes": [{"title": "ADR", "categories": [{"measurements": [{"groupId": "OG000", "value": "9.49"}]}]}, {"title": "Serious ADR", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.58"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants With Adverse Drug Reactions in Chronic Heart Failure Participants", "description": "An adverse drug reaction (ADR) was any untoward medical occurrence attributed to Selara in a chronic heart failure participant who received Selara. A serious ADR was an ADR resulting in any of the following outcomes or deemed significant for any other reason: death\u037e life-threatening experience (immediate risk of dying)\u037e initial or prolonged inpatient hospitalization\u037e persistent or significant disability/incapacity\u037e congenital anomaly. Relatedness to Selara was assessed by the physician.", "populationDescription": "The safety analysis set comprised of chronic heart failure participants who satisfied the inclusion criteria and had received Selara at least once.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Participants", "timeFrame": "52 weeks from the start date", "groups": [{"id": "OG000", "title": "Selara Tablets (Eplerenone)", "description": "Participants who received Selara as indicated in the approved local product document were observed for a period of 52 weeks. The dosage can be adjusted as per physician's discretion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1139"}]}], "classes": [{"title": "ADR", "categories": [{"measurements": [{"groupId": "OG000", "value": "5.97"}]}]}, {"title": "Serious ADR", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.79"}]}]}]}, {"type": "SECONDARY", "title": "The Number of Deaths (Overall Deaths)", "description": "Overall deaths were described with the number of deaths from any cause at the time of 52 weeks after the start of administration, regardless of the treatment status (completed or discontinued).", "populationDescription": "The efficacy analysis set comprised of chronic heart failure participants in the safety analysis set who had effectiveness evaluation (overall evaluation by the physician based upon change in clinical symptoms and laboratory findings) at least once.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "52 weeks from the start date", "groups": [{"id": "OG000", "title": "Selara Tablets (Eplerenone)", "description": "Participants who received Selara as indicated in the approved local product document were observed for a period of 52 weeks. The dosage can be adjusted as per physician's discretion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1139"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "44"}]}]}]}, {"type": "SECONDARY", "title": "The Number of Deaths (Cardiovascular Deaths)", "description": "Cardiovascular deaths were described with the number of deaths defined as any death due to cardiac failure, myocardial infarction, arrhythmia (atrial fibrillation, atrial flutter, arrhythmia supraventricular, or ventricular arrhythmia), stroke or cerebrovascular attack, and other causes related to cardiovascular system at the time of 52 weeks after the start of administration, regardless of the treatment status (completed or discontinued).", "populationDescription": "The efficacy analysis set comprised of chronic heart failure participants in the safety analysis set who had effectiveness evaluation (overall evaluation by the physician based upon change in clinical symptoms and laboratory findings) at least once.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "52 weeks from the start date", "groups": [{"id": "OG000", "title": "Selara Tablets (Eplerenone)", "description": "Participants who received Selara as indicated in the approved local product document were observed for a period of 52 weeks. The dosage can be adjusted as per physician's discretion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1139"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "15"}]}]}]}, {"type": "SECONDARY", "title": "The Overall Mortality Rate", "description": "The overall mortality rate was calculated by the incidence of all-cause death per observation time based on the person-year method (the number of deaths in 100 person-year).", "populationDescription": "The efficacy analysis set comprised of chronic heart failure participants in the safety analysis set who had effectiveness evaluation (overall evaluation by the physician based upon change in clinical symptoms and laboratory findings) at least once.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "events per 100 patient-year", "timeFrame": "52 weeks from the start date", "groups": [{"id": "OG000", "title": "Selara Tablets (Eplerenone)", "description": "Participants who received Selara as indicated in the approved local product document were observed for a period of 52 weeks. The dosage can be adjusted as per physician's discretion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1139"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4.4", "lowerLimit": "3.2", "upperLimit": "6.0"}]}]}]}, {"type": "SECONDARY", "title": "The Cardiovascular-related Mortality Rate", "description": "The cardiovascular-related mortality rate was calculated by the incidence of cardiovascular-related death per observation time based on the person-year method (the number of deaths in 100 person-year).\n\nCardiovascular deaths were defined as any death due to cardiac failure, myocardial infarction, arrhythmia (atrial fibrillation, atrial flutter, arrhythmia supraventricular, or ventricular arrhythmia), stroke or cerebrovascular attack, and other causes related to cardiovascular system at the time of 52 weeks after the start of administration, regardless of the treatment status (completed or discontinued).", "populationDescription": "The efficacy analysis set comprised of chronic heart failure participants in the safety analysis set who had effectiveness evaluation (overall evaluation by the physician based upon change in clinical symptoms and laboratory findings) at least once.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "events per 100 patient-year", "timeFrame": "52 weeks from the start date", "groups": [{"id": "OG000", "title": "Selara Tablets (Eplerenone)", "description": "Participants who received Selara as indicated in the approved local product document were observed for a period of 52 weeks. The dosage can be adjusted as per physician's discretion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1139"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.5", "lowerLimit": "0.8", "upperLimit": "2.5"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "52 weeks from the start date", "description": "The frequency of adverse events. The same event may appear as both an adverse event and a serious adverse event. However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another participant, or one participant may have experienced both serious and non-serious events during the study.", "eventGroups": [{"id": "EG000", "title": "Selara Tablets (Eplerenone)", "description": "Participants who received Selara as indicated in the approved local product document were observed for a period of 52 weeks. The dosage can be adjusted as per physician's discretion.", "deathsNumAffected": 44, "deathsNumAtRisk": 1139, "seriousNumAffected": 103, "seriousNumAtRisk": 1139, "otherNumAffected": 121, "otherNumAtRisk": 1139}], "seriousEvents": [{"term": "Disseminated intravascular coagulation", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Cardiac failure congestive", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 1139}]}, {"term": "Right ventricular failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Coronary artery stenosis", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 1139}]}, {"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Cardiac failure acute", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 1139}]}, {"term": "Angina pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 1139}]}, {"term": "Bradycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Cardiac tamponade", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Myocardial ischaemia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Cardiac ventricular thrombosis", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Ventricular fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 1139}]}, {"term": "Ventricular tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 1139}]}, {"term": "Ventricular arrhythmia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Cardiac failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 15, "numAtRisk": 1139}]}, {"term": "Atrial flutter", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Mitral valve incompetence", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Aortic valve stenosis", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Aortic valve incompetence", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Sinus node dysfunction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 1139}]}, {"term": "Arrhythmia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Atrioventricular block", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Cardiac failure chronic", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 1139}]}, {"term": "Deafness neurosensory", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Gastric haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Gastrointestinal haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 1139}]}, {"term": "Intestinal obstruction", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Death", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Hypothermia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 1139}]}, {"term": "Amyloidosis", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Infective spondylitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Bronchopulmonary aspergillosis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Pseudomembranous colitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Pyelonephritis acute", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Bacteraemia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Diverticulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 1139}]}, {"term": "Pneumonia pneumococcal", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Coronary vascular graft occlusion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Subdural haematoma", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Contusion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Spinal cord injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 1139}]}, {"term": "Spinal compression fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Femoral neck fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 1139}]}, {"term": "Fall", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Marasmus", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Hyperkalaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 1139}]}, {"term": "Dehydration", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 1139}]}, {"term": "Diabetes mellitus", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Rhabdomyolysis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Gastric cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 1139}]}, {"term": "Plasma cell myeloma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Colon cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Myelodysplastic syndrome", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Mantle cell lymphoma recurrent", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Renal neoplasm", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Tongue neoplasm malignant stage unspecified", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Prostate cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Bile duct cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Lung neoplasm malignant", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Pancreatic carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Epilepsy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Transient ischaemic attack", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 1139}]}, {"term": "Embolic stroke", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 1139}]}, {"term": "Brain stem infarction", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Cerebrovascular disorder", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Cerebral infarction", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 1139}]}, {"term": "Renal impairment", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 1139}]}, {"term": "Postrenal failure", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Interstitial lung disease", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 1139}]}, {"term": "Acute respiratory failure", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Pleural effusion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Pneumonia aspiration", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 1139}]}, {"term": "Pulmonary hypertension", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Peripheral artery occlusion", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}], "otherEvents": [{"term": "Anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 1139}]}, {"term": "Iron deficiency anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 1139}]}, {"term": "Bradycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Cardiac failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 1139}]}, {"term": "Palpitations", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Vertigo", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Constipation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 1139}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Dysphagia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Gastrointestinal disorder", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Haematochezia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Malaise", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Oedema", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 1139}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 1139}]}, {"term": "Hepatic function abnormal", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 1139}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 1139}]}, {"term": "Parotitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Fall", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 1139}]}, {"term": "Heat illness", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Post-traumatic neck syndrome", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Blood creatinine increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Blood potassium increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 1139}]}, {"term": "Blood pressure decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 9, "numAtRisk": 1139}]}, {"term": "Blood pressure increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Blood urea increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 1139}]}, {"term": "Dehydration", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 1139}]}, {"term": "Diabetes mellitus", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 1139}]}, {"term": "Dyslipidaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Hypercreatininaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Hyperkalaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 16, "numAtRisk": 1139}]}, {"term": "Hyperuricaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Hypokalaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 1139}]}, {"term": "Hyponatraemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Gouty arthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Musculoskeletal pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Pain in extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Sjogren's syndrome", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Spinal osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Carotid artery aneurysm", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Cerebral infarction", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Hypoaesthesia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Thrombotic cerebral infarction", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Acute kidney injury", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Diabetic nephropathy", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Hydronephrosis", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Nocturia", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Pollakiuria", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Prerenal failure", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Renal failure", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 1139}]}, {"term": "Renal impairment", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 24, "numAtRisk": 1139}]}, {"term": "Urge incontinence", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Gynaecomastia", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 1139}]}, {"term": "Nipple pain", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Interstitial lung disease", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 1139}]}, {"term": "Pneumonia aspiration", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Pulmonary oedema", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Upper respiratory tract inflammation", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Drug eruption", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 1139}]}, {"term": "Eczema", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Eczema asteatotic", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Pruritus", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Rash", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1139}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 10, "numAtRisk": 1139}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results."}, "pointOfContact": {"title": "Pfizer ClinicalTrials.gov Call Center", "organization": "Pfizer, Inc.", "email": "ClinicalTrials.gov_Inquiries@pfizer.com", "phone": "1-800-718-1021"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2018-12-01", "uploadDate": "2021-06-04T07:00", "filename": "Prot_000.pdf", "size": 2466901}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2020-11-19", "uploadDate": "2021-06-04T07:00", "filename": "SAP_001.pdf", "size": 657845}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "asFound": "Chronic", "relevance": "HIGH"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000077545", "term": "Eplerenone"}], "ancestors": [{"id": "D000000451", "term": "Mineralocorticoid Receptor Antagonists"}, {"id": "D000006727", "term": "Hormone Antagonists"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000062865", "term": "Diuretics, Potassium Sparing"}, {"id": "D000004232", "term": "Diuretics"}, {"id": "D000045283", "term": "Natriuretic Agents"}, {"id": "D000000959", "term": "Antihypertensive Agents"}], "browseLeaves": [{"id": "M1823", "name": "Eplerenone", "asFound": "Onset of", "relevance": "HIGH"}, {"id": "M3797", "name": "Mineralocorticoid Receptor Antagonists", "relevance": "LOW"}, {"id": "M11871", "name": "Mineralocorticoids", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M7411", "name": "Diuretics", "relevance": "LOW"}, {"id": "M30025", "name": "Diuretics, Potassium Sparing", "relevance": "LOW"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "NaAg", "name": "Natriuretic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}